Julie. you, Thank
our shows budget. in cancer platform molecules breast molecules now that And replacement this I'm the projects. development of ambition inhibitor with aimed quantity, in on importantly, for say acquired best-in-class number a with results XX% clear to or development. XXXX more Slide the the mid-XXXX, the XXXX NMEs Comparing that and to since far of few we I have to transform the Efa; to XX% now. even budget proud amcenestrant had VIII set R&D examples for transformation of pipeline. to our prioritization by in respect multiple I accomplish portfolio making BTK joined A doubled, development and engineered the our couple With trade-offs most their without for Key two, target XX estrogen molecule has extended provided is waiting focus. bolster rigorous in or R&D in oral hemophilia respect a Factor and When our for of pipeline non-alpha both quality this interleukin-X sclerosis quality, productivity receptor team degrader Sanofi profile. of that pounds to of our derisking been ranging a for to the created of Moreover, fundamentally listed increasing years quantity development to exquisitely declining and from first-in-class we've A XXXX mandating the are in a productivity recently to selective an necessary using this with oral the brain-penetrant the of our Turning the been out began organization. synthetic monitoring pharmacology we molecules the journey flat achieved for increase confidence Sanofi data reflected here, our has in immuno-oncology that Sanofi biology opportunity.
from and In proof adding from pipeline biology synthetic insulins discovery engineered the Today, highly for addition, been into has reinvigoration from vivo cell going Synthorx, even and discovery X mechanism. and clinical nanoparticles going importantly, greatly recombinant enzymes human Principia. NK through cells in our small therapies molecules, fully twists immuno-oncology mRNA research antibodies to achieved Ablynx, IRAKX from delivered These bolted drug from of selective molecules recently Kiadis Tidal, types recombinant are more new monoclonal universal our small productivity platforms supplementing drug from inspired of proteins with M&A in degrader, add The on beyond Kymab, antibodies using much diverse platforms our of to in accelerated companies improved toolbox contributing pipeline innovative collaboration with on. Sanofi is Chimera, forward.
selective receptor receptor of become Moving Slide oral for potential late-stage best-in-class is a therapy about Well, apart positive our the estrogen the the from amcenestrant makes This SERD. our molecule cancer. Among oncology setting amcenestrant, best-in-class? hormone breast it's to or all XX. molecule, degrader has assets amcenestrant backbone structure competitors. What to endocrine
can estrogen binds You in core that receptor protein the that the scaffold a from in components: as eliminate shown box think ser an X having the cellular of arm and machinery shown engages degradation to receptor cells. SERDs green
is degrader competing Sanofi's different but our scaffold SERDs, bit from entirely Now is arm a different.
As a launched result, amcenestrant setting, This possesses for years. competitive all We've amcenestrant treating to on therapy lines from efficacy, baggage but without and profile of a competing in matters the across of be to the when late. of really broad early the breast tolerability efficacy program tolerability can particularly where side early-stage SERDs. cancer, therapy effect XX adjuvant assess best-in-class women
if inhibitor. the a X the event-driven CDKX/X the to could for opportunity for will market women in bring ahead high call where cycle standard years, of study a year. in found challenge AMEERA-X we anticipate world successful, We with breast half in Our of AMEERA-X particularly is times. aromatase have fast most amcenestrant, AMEERA-X combined readout inhibitor metastatic industry in the second already This this in is within bar late-line failed But cancer. well market amcenestrant
mostly aromatase to XX% X, XX% palbociclib either or rate, fulvestrant compares X. inhibitor. I data breast with inhibitor respectable Grade Grade inhibitor. patients Phase which no benefit had received frontline not events unlike Treatment-related Our AMEERA-X clinical already rose combination in but CDKX/X SERDs, for cancer were a our adverse who in amcenestrant a showed competing metastatic some or X, Grade an kinase
planned last our We pilot reporting the dose. the our benefit encouraging of continues are enthusiastic consistent impressive of this rate presented community I III from expect response with be investigator tolerability. pace. trial for the clinical this the At we current was ASCO XX% palbociclib, Again, an for only company with data combined combination. best-in-class response to the enrolled data Phase at safety overall than demonstrated if fully amcenestrant month, Today, faster efficacy Phase profile XX% combination having at rate and we an
foray breast of is begin setting early end towards to our first adjuvant For cancer, the year. into this the set
the in and high-risk inhibitor announced a we're seminal join intolerant leading ASCO, patients cancer of oncology on working aromatase breast pleased at features. some conduct whose with world's As honored corporate to trial forces groups tumors to have
Our tamoxifen. put head-to-head amcenestrant study will against
the Recognize with population, While representing adjuvant standards. aromatase X a therapy challenges affords relatively that quickly reach of inhibitors. subset the XX% with this tolerability market early-stage study an women adjuvant adjuvant to complete fail estimated years cancer the design of breast the by to of the prescribed due opportunity to
XX, in that I point examples several of Now can in other on Slide occurred to progress please. oncology our also QX.
by cemiplimab combination cells combining Merck's a SAR'XXX, Phase without tested program, 'XXX's First, we immunosuppressive our being In with 'XXX or as monotherapy pembrolizumab. of are in potential T cells the as now therapy. Synthorx indications T interleukin-X contexts either undue expansion platform effector our regulatory best-in-class leveraging and from impressive ability expand molecule oncology to non-alpha several and selectively broad with II
our well-tolerated the inhibitors, T first cell-based negative such third therapeutics cell just expansion subpopulation is doses. molecules our found NK Sanofi's bolster into emerging on exhausted entry panel, ADCC-competent In entrant 'XXX on as partnered is combination in In are the In That I, that impressive molecule cell-based very into NK a trailblazing antibodies leverage platform a addition, objective tested focus represented cells. to stimulates in cells checkpoint PD-X XXX patients the and 'XXX molecule of as myeloid other and of our as frontier second portfolio. to with with panel, be universal will SAR'XXX combine checkpoint NK cetuximab we with the receptor by Phase well anxious with NK the a to Beyond in entered with cells immunotherapies. principally Biosciences. cell targets the ILTX,
the high other CEACAMX first-line cell drug now in combination of advanced these of universally potential in finally, expressing immunotherapy become cells cancer to portfolio. aims for Tusa in in lung III first-in-class standard our a antibody also therapy in cornerstone molecules the expect fourth Phase the to NK cancer. in panel, PD-X. I our tusamitamab targeting combine would highlight We tumors our ADC compatible well line only with CEACAMX to become molecule, And conjugate lung second care with non-squamous patients but post not for with ravtansine,
Looking cancer. beyond lung
breast year. we second CEACAMX-expressing pancreatic. readouts for in final pivotal new milestones tumor Slide trial trial includes types, potentially basket pipeline XX, quarter, started the list in registration-enabling slide, half the X namely of expected for indications. My This a Dupixent and of It additional
of about those Bill. from one You've heard
also frontline SERD from for readouts BTK and a this the where later oral And have treatment-naive late-line amcenestrant trial year myeloma out cancer. read our We indication. in in acquired rilzabrutinib, pivotal internally for for internally antibody will our Sarclisa invented which Principia, inhibitor invented anti-CDXX oral dermatology breast
also additional We to including clinic in XXXX, really some nanobodies. molecules into the half interesting of X multi-specific the put expect second an
hand commitment therapy for CFO, a Sanofi's will this priority mention I Fexanitazole sickness. Jean-Baptiste. for laboratories long-stand approved this Initiative. to And pride issue a Finally, the neglected tropical organization, in with our FDA would accomplishment. oral milestone collaboration with developed convenient was Disease that, first and disease. eradicate in with African sleeping discovered for It in to treatment the Neglected I in our fexanitazole FDA over the trobetosomisis, The African voucher for Frankfort represents that the nonprofit of Drugs review
